PharmaCyte Biotech Inc. (PMCB)
PMCB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2026-04-30, https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/0001683168-26-005836-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-04-30.
Profile
| Field | Value |
|---|---|
| Ticker | PMCB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001157075 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | NV |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$19.4M |
| Operating income | -$6.9M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $18.6M |
| Total assets | $46.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-09-14 |
| Cash and burn | $17.7M cash; operating cash flow -$985K a quarter. | Report 2026-07-31 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-09-11 |
| Reverse splits, 3 years | 1; latest 1-for-19 on 2026-11-13 | Source 2026-11-13 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2025-12-05 |
| Auditor | CBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 2 times in 24 months | 8-K 4.01 2026-10-16 |
| Late filings, 12 months | 1 NT notice | NT 10-Q 2025-12-15 |
| Insider trades, 12 months | Bought $129K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-07-31 | $0 | -$5.1M | -$781K | $17.7M | No debt tags | $0 | 10-Q 2026-09-14 |
| Q4 2026 2026-04-30 | $0 | -$4.4M | -$1.4M | $18.6M | No debt tags | $0 | 10-K 2026-07-29 |
| Q3 2026 2026-01-31 | $0 | $747K | -$787K | $20.2M | No debt tags | $0 | 10-Q 2026-03-17 |
| Q2 2026 2025-10-31 | $0 | -$7.4M | -$980K | $15.4M | No debt tags | $0 | 10-Q 2025-12-18 |
| Q1 2026 2025-07-31 | $0 | -$8.4M | -$2.0M | $13.2M | No debt tags | $0 | 10-Q 2026-09-14 |
| Q4 2025 2025-04-30 | $0 | $11.7M | -$1.0M | $15.2M | No debt tags | $0 | 10-K 2026-07-29 |
| Q3 2025 2025-01-31 | $0 | -$3.0M | -$510K | $16.4M | No debt tags | $0 | 10-Q 2026-03-17 |
| Q2 2025 2024-10-31 | $0 | -$1.5M | -$1.1M | $20.8M | No debt tags | $0 | 10-Q 2025-12-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2025-09-17 |
| Latest annual report FORM 10-K FOR APRIL 2026 | 10-K | 2026-07-29 |
| Latest quarterly / interim FORM 10-Q FOR JUL 2026 | 10-Q | 2026-09-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-13 |
| Latest proxy DEFINITIVE PROXY STATEMENT | DEF 14A | 2026-03-09 |
Source: SEC EDGAR submissions feed, 473 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.3% |
| 1 month | -1.2% |
| 3 months | -36.1% |
| Year to date | -51.4% |
| 1 year | -55.5% |
| From 52-week high | -71.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CGTX | Cognition Therapeutics Inc. | $0.6388 | -6.03% | $60.8M |
| OKYO | OKYO Pharma Limited | $1.18 | -12.96% | $61.7M |
| CSBR | Champions Oncology Inc. | $4.68 | -0.53% | $65.1M |
| ATRA | Atara Biotherapeutics Inc. | $6.40 | -16.88% | $65.2M |
| CRDF | Cardiff Oncology Inc. | $0.8477 | +16.75% | $65.9M |
| GRML | Greenland Mines Ltd. | $3.50 | -3.05% | $51.9M |
| NMRA | Neumora Therapeutics Inc. | $0.3695 | -13.85% | $69.4M |
| ELOX | Eloxx Pharmaceuticals Inc. | $12.75 | -3.04% | $51.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier